Status message

Active context: kki_bg_colors_yellow

A Phase 2, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

Principal Investigator:
Robert
Findling

A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)

To evaluate the safety and tolerability of SPD489, administered as a daily morning dose (5, 10, 15, 20, and 30mg/day) in the treatment of preschool children (4-5 years of age inclusive at the time of consent) with attention-deficit/hyperactivity disorder (ADHD).

March is Brain Injury Awareness Month

Brain Injury Awareness Month

Help raise awareness and support for brain injury research, treatment and education. Learn more about our program.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.